Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In Vivo CAR-T Therapy Targeting CD20 for Hematological Malignancies
NCT07362602Phase 1Not yet recruiting
- Sponsor
- 923rd Hospital of the Joint Logistics Support Force
- Start
- Jan 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, open-label trial in hematological malignancies, B cell lymphoma and Lymphocytic leukemia (2 arms), sponsored by 923rd Hospital of the Joint Logistics Support Force. Primary endpoints: Dose Limiting Toxicity at 28 days, Incidence of adverse effects at 2 years and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Conditions
hematological malignanciesB cell lymphomaLymphocytic leukemia
Beyond the preview
Go deeper on NCT07362602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362602.